Welcome to our dedicated page for Kalvista Pharm SEC filings (Ticker: KALV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
KalVista Pharmaceuticals SEC filings document 8-K disclosures for a commercial-stage pharmaceutical company focused on oral rare-disease therapies. The filings cover results of operations and financial condition, Regulation FD materials, product-revenue updates tied to EKTERLY, and the company’s Nasdaq-listed common stock.
The filing record also includes governance and compensation disclosures, board committee changes, executive appointments, material definitive agreements, and capital-structure actions. Financing disclosures include the completed sale of 3.250% convertible senior notes due 2031, while other reports describe exhibit filings, furnished press releases, Inline XBRL cover data, and formal disclosure treatment under the Exchange Act.
KalVista Pharmaceuticals, Inc. Schedule 13G: Glazer Capital, LLC and Paul J. Glazer report beneficial ownership of 2,581,700 shares of Common Stock, representing 4.85% of the class. The filing states the Reporting Persons "have ceased to be the beneficial owner of more than five percent of the class of securities."
The statement lists shared voting and dispositive power over the 2,581,700 shares and provides business addresses and CUSIP 483497103. The filing is a routine ownership disclosure under Schedule 13G reporting an ownership position below the 5% threshold.
Chiesi Farmaceutici, through its wholly owned subsidiary Skyline Merger Sub, has offered to acquire all outstanding shares of KalVista Pharmaceuticals for $27.00 per share in cash, subject to the terms and conditions in the Offer to Purchase.
The filing states the HSR Act waiting period expired at 11:59 p.m. ET on May 28, 2026; the German GWB prohibition criteria were not met on May 27, 2026; and the Italian foreign direct investment authority notified Parent it will not object on May 29, 2026. The filing also discloses twelve demand letters and two individual complaints alleging disclosure deficiencies and seeking injunctions, rescission or damages.
KalVista Pharmaceuticals responded to the Chiesi tender offer and amended its Schedule 14D-9 to add voluntary supplemental disclosures. The filing reiterates the $27.00 per share cash offer and summarizes Parent proposals of $24.00, $26.50 and a final $27.00 per-share offer that led to a Merger Agreement.
The amendment discloses two stockholder complaints in New York state court challenging disclosures, certain demand letters, management financial projections (including $446M projected 2029 revenue) and Centerview’s valuation ranges. The Company states the claims are without merit, notes regulatory clearances including HSR expiration and certain foreign reviews, and supplements background on negotiations and CVR discussions.
KalVista Pharmaceuticals chief development officer Christopher Yea reported an option exercise paired with an open-market sale of common stock. He exercised employee stock options to acquire 33,800 shares at an exercise price of $7.07 per share, fully exercising that option grant. On the same date, he sold 33,800 common shares in open-market transactions at a weighted average price of $26.7818 per share, with individual trades ranging from $26.78 to $26.79. Following these transactions, Yea directly owns 229,918 shares of KalVista common stock.
KALV submitted a Form 144 notice to sell 33,800 shares of Common Stock on 05/27/2026. The filing lists the planned sale as a Stock Option Exercise with cash proceeds. The excerpt also shows recent open-market sales by Christopher M. Yea of 1,966; 2,358; and 1,108 shares on May 26, May 22, and May 18, 2026 respectively.
KalVista Pharmaceuticals' chief development officer Christopher Yea reported routine equity activity involving restricted stock units and a small share sale. He exercised 3,125 restricted stock units, receiving an equal number of common shares for no cash consideration. To cover tax withholding from this RSU vesting, he sold 1,966 common shares in an open-market "sell to cover" transaction that the company states was not discretionary. After these transactions, Yea directly holds 229,918 shares of common stock. His RSU award totals 25,000 units, with 1/16 of the grant vesting on each quarterly anniversary of the August 22, 2024 vesting commencement date, contingent on continued service.
KalVista Pharmaceuticals’ Chief Commercial Officer Nicole Sweeny reported routine equity compensation activity. On May 22, 2026, she exercised 5,000 Restricted Stock Units (RSUs), each converting into one share of common stock for no cash cost. A Form 4 footnote explains that on May 26, 2026 she sold 1,489 common shares at $26.7778 per share solely to cover tax withholding obligations through a “sell to cover” transaction, which the company notes was not a discretionary sale. After these transactions, she directly holds 59,291 shares of common stock and 40,000 RSUs that continue to vest quarterly, subject to continued service.
KalVista Pharmaceuticals’ Chief Medical Officer, Paul K. Audhya, reported routine equity compensation activity and a related tax sale. On May 22, 2026, he exercised 5,000 Restricted Stock Units, receiving 5,000 shares of common stock for no cash consideration as part of RSU vesting.
On May 26, 2026, he sold 2,239 shares of common stock at $26.7778 per share in a “sell to cover” transaction to satisfy tax withholding obligations, which the filing states was not a discretionary trade. Following these transactions, he directly held 150,260 shares of common stock and 40,000 RSUs.
KalVista Pharmaceuticals’ CEO Benjamin L. Palleiko reported RSU vesting and a related tax sale. On May 21, 2026, 23,250 Restricted Stock Units converted into an equal number of common shares for no cash payment. On May 22, 2026, he sold 10,926 common shares at an average price of $26.7844 per share to cover tax withholding obligations from this RSU vesting, a non-discretionary “sell to cover” transaction. Following these transactions, he directly holds 479,989 common shares and 255,750 RSUs, so the tax-related sale represents a small portion of his overall equity position.
KalVista Pharmaceuticals Chief Commercial Officer Nicole Sweeny reported routine equity compensation activity. On May 21, 2026, 6,250 restricted stock units converted into the same number of shares of common stock at no cost upon vesting. Each RSU represents a right to receive one share.
On May 22, 2026, she sold 1,861 shares of common stock at an average price of $26.7844 per share. According to the disclosure, this sale was executed solely to cover tax withholding obligations from the RSU vesting as a “sell to cover” transaction and was not a discretionary trade. After these transactions, Sweeny directly holds 55,780 shares of KalVista common stock.